Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus. The durability of the glycemic control obtained is dependent on the degree to which beta-cell function can be maintained, but sulfonylureas appear neither to increase nor to decrease the underlying rate of loss of beta-cell function. As sulfonylureas act by enhancing insulin secretion, they are probably best used close to the time when diabetes is diagnosed when beta-cell function is at its greatest and their utility can be extended by judicious use in combination with agents that improve glycemia by different modes of action, including insulin.

Original publication

DOI

10.1016/j.metabol.2006.02.006

Type

Conference paper

Publication Date

05/2006

Volume

55

Pages

S2 - S5

Keywords

Cerebral Cortex, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Insulin, Islets of Langerhans, Metformin, Prospective Studies, Sulfonylurea Compounds, United Kingdom